The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Characterization of CD22 expression in acute lymphoblastic leukemia
Open accessAbstract
Background: CD22 is a B‐lineage differentiation antigen that has emerged as a leading therapeutic target in acute lymphoblastic leukemia (ALL). Procedure: Properties of CD22 expression relevant to therapeutic targeting were characterized in primary samples obtained from children and young adults with relapsed and chemotherapy refractory B‐precursor (pre‐B) ALL. Results: CD22 expression was demonstrated in all subjects (n = 163) with detection on at least 90% of blasts in 155 cases. Median antigen site density of surface CD22 was 3,470 sites/cell (range 349–19,653, n = 160). Blasts from patients with known 11q23 (MLL) rearrangement had lower site density (median 1,590 sites/cell, range 349–3,624, n = 20 versus 3,853 sites/cell, range 451–19,653, n = 140; P = <0.0001) and 6 of 21 cases had sub‐populations of blasts lacking CD22 expression (22%–82% CD22 +). CD22 expression was maintained in serial studies of 73 subjects, including those treated with anti‐CD22 targeted therapy. The levels of soluble CD22 in blood and marrow by ELISA were low and not expected to influence the pharmacokinetics of anti‐CD22 directed agents. Conclusions: These characteristics make CD22 an excellent potential therapeutic target in patients with relapsed and chemotherapy‐refractory ALL, although cases with MLL rearrangement require close study to exclude the presence of a CD22‐negative blast population. Pediatr Blood Cancer Published 2015. This article is a U.S. Government work and is in the public domain in the USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Self-citationAcute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Self-citation
Metadata
- Authors
- Shah, N. N., Stevenson, M. S., Yuan, C. M., Richards, K., Delbrook, C., Kreitman, R. J., Pastan, I., & Wayne, A. S.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2015-03
- Volume
- 62
- Issue
- 6
- Pages
- 964-969
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W1943300686
- Cited by
- 179
- References
- 1
- FWCI
- 14.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of CD22 expression in acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1002/pbc.25410
- The paper
- Shah, N. N., Stevenson, M. S., Yuan, C. M., Richards, K., Delbrook, C., Kreitman, R. J., Pastan, I., & Wayne, A. S. (2015). Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.25410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.